PitchBook-2025年二季度医疗技术公共报表和估值指南（英）-2025_6页_635kb

报告摘要

Medtech public firms outperformed broader markets in the second quarter of 2025, with subsectors achieving median double-digit share price gains, surpassing the S&P 500's 9.7% gain. This follows a trend of strong performance driven by investor focus on higher-risk, higher-reward companies like diagnostic firms.

Notable stock performers include Tempus AI (58% gain) and Exact Sciences (57% gain), reflecting renewed interest in diagnostic technologies. Grail, despite a 150% increase since IPO, trades at a low valuation relative to its purchase price history.
IPO activity is resurging after a period of scarcity, with Caris Life Sciences leading as a significant example (raised ~$500 million at a valuation over $7 billion), potentially encouraging more companies to pursue listings.
Valuations across the medtech sector are converging due to lower risk appetites and economic factors, with consensus forecasting flat revenue growth in 2026, which could lead to significant share price shifts if industry dynamics surprise.

Revenue and EBITDA metrics show varied growth, with some companies experiencing high increases in specific subsectors, while others face pressure from broader market and policy risks.
Multiples (e.g., EV/LTM revenue) have remained relatively stable, but convergence is accelerating, with potential shifts expected based on industry and macroeconomic conditions.

For detailed company-specific data, refer to the full PitchBook report.

展开完整摘要